This week’s Immunology update highlights regulatory and clinical developments across autoimmune disease, oncology, and immune-cell programming platforms.
In Today’s Newsletter
Dive deeper
🧬 Regeneron fianlimab Phase 3 melanoma update [1] [US • 15 May 2026]
https://investor.regeneron.com/news-releases/news-release-details/regeneron-provides-update-phase-3-trial-fianlimab-lag-3
Context: The trial missed statistical significance for PFS versus pembrolizumab, though high-dose combination median PFS was 11.5 months versus 6.4 months.
Key point: Phase 3 tested fianlimab (Regeneron; LAG-3 inhibitor) plus cemiplimab (PD-1 inhibitor) in first-line unresectable locally advanced or metastatic melanoma.
Implication: May influence prescriber choice and payer reviews pending full data.
🧫 Fate Therapeutics FT819 lupus nephritis plan [2] [US • 13 May 2026]
https://www.globenewswire.com/news-release/2026/05/13/3293996/24675/en/Fate-Therapeutics-Reports-First-Quarter-2026-Financial-Results-and-Business-Updates.html
Context: RECLAIM-LN Phase 2 is expected to start dosing in 2H 2026 and enroll about 53 patients, with complete renal response at six months as primary endpoint.
Key point: FT819 (Fate Therapeutics; off-the-shelf CD19 CAR T) is being advanced in autoimmune diseases, including SLE with lupus nephritis.
Implication: May influence prescriber choice and payer reviews pending full data.
💰 CREATE Medicines $122 million Series B [3] [US • 14 May 2026]
https://www.prnewswire.com/news-releases/create-medicines-announces-122-million-series-b-financing-to-advance-in-vivo-car-pipeline-in-autoimmune-disease-and-oncology-302771778.html
Context: The company closed a $122 million Series B to advance CRT-402, a CD19 in vivo CAR-T therapy, plus dual CAR CD19 x BCMA and oncology programs.
Key point: CREATE Medicines is developing an mRNA-LNP in vivo immune programming platform across autoimmune disease and oncology.
Implication: Signals pipeline investment and modality expansion.
🛡️ Liberate Bio LIB820 in vivo CAR-M data [4] [US • 13 May 2026]
https://www.businesswire.com/news/home/20260513069585/en/Liberate-Bio-Presents-New-Preclinical-Data-Supporting-First-Clinical-Evaluation-of-In-Vivo-CAR-M-Program-LIB820-in-Autoimmune-Disease
Context: New preclinical data support selective myeloid programming, peripheral B-cell depletion, and a differentiated cytokine profile.
Key point: LIB820 (Liberate Bio; anti-CD19 in vivo CAR-M) uses LNP-delivered mRNA to program monocytes and macrophages.
Implication: May influence prescriber choice and payer reviews pending full data.
⚡ SetPoint Medical RA cost-effectiveness study [5] [US • 14 May 2026]
https://www.biospace.com/press-releases/setpoint-medical-announces-publication-of-cost-effectiveness-study-confirming-neuroimmune-modulation-can-reduce-total-cost-of-care-and-improve-quality-of-life-for-patients-with-rheumatoid-arthritis
Context: A Markov model using RESET-RA inputs projected lifetime savings of more than $350,000 per patient versus standard pharmacologic care.
Key point: SetPoint System (SetPoint Medical; neuroimmune modulation device) is FDA-approved for adults with moderate-to-severe rheumatoid arthritis.
Implication: Could inform practice and payer discussions; interpretation depends on study design and confounding control.
💊 Zenas BioPharma ZB021 Phase 1 dosing [6] [US, China • 13 May 2026]
https://www.globenewswire.com/news-release/2026/05/13/3293817/0/en/Zenas-BioPharma-Announces-First-Subject-Dosed-in-Phase-1-Clinical-Trial-of-ZB021-a-Novel-Potentially-Best-in-Class-Oral-IL-17AA-AF-Inhibitor.html
Context: First subject was dosed in Phase 1, with SAD and MAD data expected by year-end 2026 and psoriasis POC data anticipated in 2027.
Key point: ZB021 (Zenas BioPharma; oral IL-17AA/AF inhibitor) is being studied in partnership with InnoCare Pharma in China.
Implication: May influence prescriber choice and payer reviews pending full data.
🩹 Palvella QTORIN rapamycin Phase 2 TOIVA data [7] [US • 15 May 2026]
https://www.globenewswire.com/news-release/2026/05/15/3295760/0/en/palvella-therapeutics-announces-new-data-from-the-phase-2-toiva-trial-of-qtorin-rapamycin-in-cutaneous-venous-malformations-presented-at-the-83rd-annual-meeting-of-the-society-for-.html
Context: Patients with baseline bleeding had statistically significant cVM-IGA Bleeding improvement at Week 12, with n=4.
Key point: TOIVA is a Phase 2 single-arm, open-label, baseline-controlled trial of topical QTORIN rapamycin in cutaneous venous malformations.
Implication: May influence prescriber choice and payer reviews pending full data.
Why it matters
- In vivo and off-the-shelf immune-cell programming remains a major autoimmune investment theme, with CREATE, Fate, and Liberate advancing distinct platforms. [2][3][4]
- Regeneron’s fianlimab result shows that numeric PFS separation may not be enough without statistical significance in checkpoint combinations. [1]
- SetPoint’s RA analysis adds payer-facing health-economic evidence for a device-based autoimmune treatment model. [5]
- Zenas is testing whether IL-17 pathway inhibition can move into an oral format for immune-mediated disease. [6]
- Palvella’s TOIVA update highlights rare dermatology indications where no FDA-approved therapy is cited by the company. [7]
🧰 See our full range of services. Discover how we can help you.
📚 View the full Immunology archive on our research hub page.
🚀 Accelerate your success. Contact us now
📂 Explore our case studies. See examples of our work.
💡 Read our insights. Learn from our latest reports and analysis
🎯 Catch up on the Top Immunology news from the past two weeks, curated by the Lucidquest team.
FAQ
Did Regeneron’s fianlimab plus cemiplimab trial meet its primary endpoint?
No. Regeneron said the Phase 3 trial did not reach statistical significance for PFS versus pembrolizumab in first-line unresectable or metastatic melanoma. [1]
What is Fate Therapeutics testing in RECLAIM-LN?
Fate plans to test FT819, an off-the-shelf CD19 CAR T, in refractory moderate-to-severe SLE with lupus nephritis. The planned primary endpoint is complete renal response at six months. [2]
What will CREATE Medicines use its Series B funding for?
CREATE said the $122 million financing will support CRT-402, dual CAR CD19 x BCMA, and oncology programs built on its mRNA-LNP in vivo immune programming platform. [3]
How is Liberate Bio’s LIB820 different from in vivo CAR-T approaches?
LIB820 is designed to program monocytes and macrophages, not T cells, using anti-CD19 CAR mRNA delivered by LNP. Data are preclinical. [4]
What did SetPoint Medical’s cost-effectiveness study claim?
The company said a peer-reviewed model projected the SetPoint System could reduce costs and improve quality-adjusted life-years versus standard pharmacologic care in RA. [5]
What was new in Palvella’s TOIVA update?
Palvella reported Week 12 bleeding improvement on cVM-IGA Bleeding among patients with bleeding at baseline, with n=4. [7]
Entities / Keywords
Regeneron Pharmaceuticals, fianlimab, LAG-3 inhibitor, cemiplimab, PD-1 inhibitor, pembrolizumab, Opdualag, melanoma
Fate Therapeutics, FT819, RECLAIM-LN, CD19 CAR T, iPSC-derived cell therapy, SLE, lupus nephritis, FT839, FT836
CREATE Medicines, CRT-402, in vivo CAR-T, mRNA-LNP, CD19, BCMA, MT-303, hepatocellular carcinoma
Liberate Bio, LIB820, CAR-M, monocytes, macrophages, RAPTOR LNP, B-cell depletion, systemic sclerosis, LIB810
SetPoint Medical, SetPoint System, neuroimmune modulation, vagus nerve stimulation, rheumatoid arthritis, RESET-RA
Zenas BioPharma, ZB021, oral IL-17AA/AF inhibitor, InnoCare Pharma, plaque psoriasis
Palvella Therapeutics, QTORIN rapamycin, TOIVA, cutaneous venous malformations, cVM-IGA Bleeding
